Cagrilintide placebo

DRUG2 trials

Sponsors

Novo Nordisk A/S

Conditions

Alcohol-related Liver DiseaseObesity

Phase 1

A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants

CompletedNCT05804162

Novo Nordisk A/SObesity

Start: 2023-04-12End: 2023-09-18Updated: 2024-11-01

Phase 2

Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

CompletedNCT06409130

Novo Nordisk A/SAlcohol-related Liver Disease

Start: 2024-05-20End: 2026-01-12Updated: 2026-03-12

Related Papers

Cagrilintide is not associated with clinically relevant <scp>QTc</scp> prolongation: A thorough <scp>QT</scp> study in healthy participants

Diabetes Obesity and Metabolism2024-09-161 citations